GlassScriptPhysician profile
Manuel A Estrada
NPI 1740451517
$4,827.32
in general payments reported to CMS, 2019-2025
24 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $657 · 2021: $1,156 · 2022: $203 · 2023: $271 · 2024: $294 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.70 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $633.53 | 2020-2021 | |
| Merz North America, INC. | $432.49 | 2021-2022 | |
| Abiomed | $390.56 | 2023-2024 | Impella |
| Teva Pharmaceuticals USA, INC. | $271.93 | 2019-2025 | Uzedy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $224.99 | 2021-2022 | |
| Lilly USA, LLC | $217.23 | 2019-2022 | |
| Melinta Therapeutics, LLC | $205.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $168.97 | 2019 | |
| Sunovion Pharmaceuticals INC. | $167.31 | 2019-2020 | |
| Insmed, INC. | $153.35 | 2023 | Arikayce |
| Abbvie INC. | $136.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.98 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $124.98 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.41 | 2020 | |
| Astellas Pharma US INC | $114.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $99.89 | 2020-2022 | |
| Genentech USA, INC. | $89.68 | 2019 | |
| Amgen INC. | $85.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $64.38 | 2019-2024 | |
| Heron Therapeutics, INC. | $37.10 | 2022 | |
| Pfizer INC. | $33.54 | 2021 | |
| Neurocrine Biosciences, INC. | $20.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.